NASDAQ:FRLN Freeline Therapeutics (FRLN) Stock Price, News & Analysis → Urgent Nvidia Warning (From Altimetry) (Ad) Free FRLN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$6.48▼$6.4850-Day Range$6.43▼$6.4952-Week Range$2.11▼$8.74VolumeN/AAverage Volume12,055 shsMarket Capitalization$28.12 millionP/E RatioN/ADividend YieldN/APrice Target$4.83 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial Media Get Freeline Therapeutics alerts: Email Address Freeline Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside25.4% Downside$4.83 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.01) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.07 out of 5 starsMedical Sector904th out of 908 stocksBiotechnology Industry18th out of 19 stocks 1.0 Analyst's Opinion Consensus RatingFreeline Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageFreeline Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for FRLN. Previous Next 0.0 Dividend Strength Dividend YieldFreeline Therapeutics does not currently pay a dividend.Dividend GrowthFreeline Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FRLN. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for FRLN on MarketBeat in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Freeline Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.90% of the stock of Freeline Therapeutics is held by insiders.Percentage Held by Institutions46.26% of the stock of Freeline Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Freeline Therapeutics are expected to grow in the coming year, from ($1.01) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Freeline Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Freeline Therapeutics is -1.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFreeline Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. About Freeline Therapeutics Stock (NASDAQ:FRLN)Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.Read More Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. FRLN Stock News HeadlinesApril 24, 2024 | globenewswire.comFreeline to Present New Data on its Gaucher and Parkinson's Disease Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual MeetingFebruary 25, 2024 | benzinga.comFreeline Therapeutics Stock (NASDAQ:FRLN) Dividends: History, Yield and DatesMay 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.February 20, 2024 | finance.yahoo.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 20, 2024 | globenewswire.comAcquisition of Freeline by Syncona Becomes EffectiveFebruary 13, 2024 | finanznachrichten.deFreeline Therapeutics Shareholders Approve Acquisition by SynconaFebruary 12, 2024 | finance.yahoo.comFreeline Shareholders Approve Acquisition by SynconaFebruary 9, 2024 | uk.finance.yahoo.comFreeline Therapeutics Holdings plc (FRLN)May 2, 2024 | Stansberry Research (Ad)Urgent dollar warningYour 2024 Election Money Blueprint Voters are angrier than ever, and it's likely to keep getting worse. The media and Wall Street keep declaring how great the economy supposedly is... but no one – besides the ultra-rich – seems to feel that way. Protect yourself with this one simple move today.December 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SRC, EAR, PATI, FRLNNovember 30, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Freeline Therapeutics Holdings (FRLN)November 29, 2023 | businesswire.comFREELINE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Freeline ...November 23, 2023 | finance.yahoo.comFreeline (FRLN) Shares Rise on Merger Agreement With SynconaNovember 22, 2023 | finanznachrichten.deSyncona Limited to Acquire Freeline TherapeuticsNovember 22, 2023 | tmcnet.comFRLN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Freeline Therapeutics Holdings plc Is Fair to ShareholdersNovember 18, 2023 | seekingalpha.comFRLN Freeline Therapeutics Holdings plcNovember 5, 2023 | morningstar.comFreeline Therapeutics Holdings PLC ADR FRLNOctober 28, 2023 | markets.businessinsider.comFreeline Therapeutics: Promising Initial Efficacy Data and Potential for High Revenues Justify Buy RatingOctober 25, 2023 | finance.yahoo.comFreeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressOctober 19, 2023 | finance.yahoo.comHere's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn SituationOctober 18, 2023 | markets.businessinsider.comWhere Freeline Therapeutics Stands With AnalystsOctober 16, 2023 | finance.yahoo.comFreeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressOctober 6, 2023 | marketwatch.comFreeline Therapeutics ADRs Rise 14% Following Positive Trial Data on FLT201October 5, 2023 | markets.businessinsider.comPromising Gaucher Disease Trial Results and Potential Parkinson’s Disease Impact Bolster Analyst’s Buy Rating for Freeline Therapeutics HoldingsOctober 4, 2023 | benzinga.comWhy Is Gene Therapy Player Freeline Therapeutics Stock Trading Higher Today?October 4, 2023 | markets.businessinsider.comFreeline Reports Positive Data From First Cohort Of Phase 1/2 GALILEO-1 Trial Of FLT201October 4, 2023 | finance.yahoo.comFreeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseSee More Headlines Receive FRLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:FRLN CUSIPN/A CIK1810031 Webwww.freeline.life Phone44-0-14-3890-6870FaxN/AEmployees152Year FoundedN/APrice Target and Rating Average Stock Price Target$4.83 High Stock Price Target$6.50 Low Stock Price Target$3.00 Potential Upside/Downside-25.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.5939) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-150.46% Return on Assets-97.01% Debt Debt-to-Equity RatioN/A Current Ratio1.95 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.07 per share Price / Book0.54Miscellaneous Outstanding Shares4,340,000Free Float4,259,000Market Cap$28.12 million OptionableNot Optionable Beta0.66 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Michael J. Parini J.D. (Age 49)CEO & Executive Director Comp: $2.16MMr. Paul M. Schneider (Age 53)CFO & Director Dr. Henning R. Stennicke Ph.D. (Age 56)Chief Scientific Officer Ms. Nicole Jones SPHR (Age 53)Chief People Officer Mr. James Bircher (Age 56)Chief Technical Operations Officer Dr. Pamela Foulds M.D. (Age 54)Chief Medical Officer Ms. Naomi AokiSenior Vice President of Corporate Communications & Investor RelationsMs. Amy J. Spandau (Age 49)Interim Head of Finance More ExecutivesKey CompetitorsEvaxion Biotech A/SNASDAQ:EVAXLianBioNASDAQ:LIANOcuphire PharmaNASDAQ:OCUPPHAXIAM TherapeuticsNASDAQ:PHXMSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInstitutional OwnershipPenderFund Capital Management Ltd.Bought 60,401 shares on 2/14/2024Ownership: 1.391%View All Institutional Transactions FRLN Stock Analysis - Frequently Asked Questions Should I buy or sell Freeline Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FRLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FRLN, but not buy additional shares or sell existing shares. View FRLN analyst ratings or view top-rated stocks. What is Freeline Therapeutics' stock price target for 2024? 2 brokerages have issued 1-year price objectives for Freeline Therapeutics' shares. Their FRLN share price targets range from $3.00 to $6.50. On average, they expect the company's share price to reach $4.83 in the next year. This suggests that the stock has a possible downside of 25.4%. View analysts price targets for FRLN or view top-rated stocks among Wall Street analysts. How were Freeline Therapeutics' earnings last quarter? Freeline Therapeutics Holdings plc (NASDAQ:FRLN) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($12.90) EPS for the quarter, topping the consensus estimate of ($15.20) by $2.30. When did Freeline Therapeutics' stock split? Freeline Therapeutics shares reverse split on the morning of Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Freeline Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME). When did Freeline Therapeutics IPO? Freeline Therapeutics (FRLN) raised $126 million in an initial public offering (IPO) on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:FRLN) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingYour bank is lying to you.MyBankTrackerTrump just won 2024Porter & CompanyA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Freeline Therapeutics Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.